Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 204 | 2025 | 17569 | 7.660 |
Why?
|
Botswana | 151 | 2025 | 1058 | 7.070 |
Why?
|
Pregnancy Complications, Infectious | 64 | 2025 | 2185 | 6.060 |
Why?
|
Anti-HIV Agents | 81 | 2024 | 4573 | 4.770 |
Why?
|
Infectious Disease Transmission, Vertical | 49 | 2024 | 1354 | 3.880 |
Why?
|
HIV-1 | 74 | 2024 | 6963 | 3.370 |
Why?
|
Anti-Retroviral Agents | 43 | 2023 | 1789 | 3.220 |
Why?
|
Nevirapine | 29 | 2023 | 273 | 3.050 |
Why?
|
Circumcision, Male | 9 | 2020 | 148 | 2.790 |
Why?
|
Antiretroviral Therapy, Highly Active | 40 | 2024 | 1903 | 2.520 |
Why?
|
Reverse Transcriptase Inhibitors | 17 | 2020 | 620 | 2.160 |
Why?
|
Breast Feeding | 28 | 2023 | 1363 | 2.110 |
Why?
|
Drug Resistance, Viral | 23 | 2024 | 869 | 2.050 |
Why?
|
Benzoxazines | 10 | 2024 | 320 | 1.910 |
Why?
|
Heterocyclic Compounds, 3-Ring | 10 | 2024 | 296 | 1.830 |
Why?
|
Oxazines | 10 | 2024 | 358 | 1.580 |
Why?
|
Pregnancy Outcome | 24 | 2025 | 2972 | 1.570 |
Why?
|
Pregnancy | 102 | 2025 | 30255 | 1.450 |
Why?
|
Viral Load | 40 | 2024 | 3396 | 1.430 |
Why?
|
HIV Seropositivity | 11 | 2024 | 966 | 1.420 |
Why?
|
Infant Formula | 7 | 2021 | 194 | 1.340 |
Why?
|
Pyridones | 10 | 2024 | 819 | 1.260 |
Why?
|
Zidovudine | 16 | 2023 | 625 | 1.240 |
Why?
|
Piperazines | 10 | 2024 | 2554 | 1.210 |
Why?
|
Stillbirth | 15 | 2024 | 381 | 1.180 |
Why?
|
CD4 Lymphocyte Count | 22 | 2023 | 2596 | 1.060 |
Why?
|
Ritonavir | 9 | 2016 | 332 | 1.010 |
Why?
|
Premature Birth | 17 | 2025 | 1829 | 0.990 |
Why?
|
Prenatal Exposure Delayed Effects | 8 | 2019 | 2539 | 0.970 |
Why?
|
RNA, Viral | 22 | 2021 | 2874 | 0.960 |
Why?
|
Infant, Newborn | 68 | 2025 | 26421 | 0.960 |
Why?
|
Folic Acid | 5 | 2025 | 1337 | 0.900 |
Why?
|
Infant Mortality | 8 | 2019 | 752 | 0.870 |
Why?
|
Lactation | 4 | 2022 | 392 | 0.820 |
Why?
|
Mass Screening | 8 | 2021 | 5458 | 0.810 |
Why?
|
Viremia | 4 | 2024 | 726 | 0.780 |
Why?
|
Female | 189 | 2025 | 397187 | 0.770 |
Why?
|
Adenine | 8 | 2024 | 995 | 0.750 |
Why?
|
Child Development | 6 | 2019 | 2330 | 0.730 |
Why?
|
Adult | 129 | 2025 | 223646 | 0.670 |
Why?
|
Alkynes | 9 | 2024 | 326 | 0.660 |
Why?
|
Humans | 236 | 2025 | 768171 | 0.640 |
Why?
|
Cyclopropanes | 9 | 2024 | 436 | 0.630 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2023 | 2204 | 0.630 |
Why?
|
Paternal Exposure | 1 | 2019 | 100 | 0.630 |
Why?
|
Infant | 50 | 2024 | 36535 | 0.590 |
Why?
|
Postpartum Period | 8 | 2024 | 1197 | 0.580 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 283 | 0.550 |
Why?
|
Anemia | 3 | 2025 | 1514 | 0.530 |
Why?
|
Hepatitis B | 5 | 2024 | 711 | 0.530 |
Why?
|
Diarrhea, Infantile | 1 | 2016 | 100 | 0.520 |
Why?
|
Maternal Health Services | 1 | 2021 | 472 | 0.520 |
Why?
|
HIV Protease Inhibitors | 7 | 2018 | 430 | 0.520 |
Why?
|
Cytomegalovirus Infections | 2 | 2020 | 837 | 0.510 |
Why?
|
Erythrocytes | 1 | 2024 | 2418 | 0.490 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 85 | 0.480 |
Why?
|
Young Adult | 46 | 2025 | 60066 | 0.480 |
Why?
|
Vascular Diseases | 1 | 2023 | 1162 | 0.470 |
Why?
|
Hepatitis B virus | 6 | 2024 | 533 | 0.460 |
Why?
|
Contraception Behavior | 1 | 2016 | 186 | 0.450 |
Why?
|
Lamivudine | 7 | 2024 | 367 | 0.440 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.430 |
Why?
|
Neutropenia | 4 | 2017 | 892 | 0.420 |
Why?
|
Prilocaine | 1 | 2012 | 21 | 0.420 |
Why?
|
Respiratory System | 1 | 2016 | 564 | 0.420 |
Why?
|
Health Knowledge, Attitudes, Practice | 7 | 2024 | 4055 | 0.420 |
Why?
|
Foreskin | 1 | 2012 | 33 | 0.420 |
Why?
|
Incidence | 15 | 2024 | 21538 | 0.410 |
Why?
|
Hepatitis B, Chronic | 3 | 2023 | 413 | 0.410 |
Why?
|
Adolescent | 41 | 2025 | 89169 | 0.410 |
Why?
|
Hepatitis C | 1 | 2022 | 1595 | 0.400 |
Why?
|
DNA, Viral | 9 | 2023 | 2204 | 0.400 |
Why?
|
Medicine, African Traditional | 1 | 2012 | 31 | 0.390 |
Why?
|
Equipment and Supplies | 1 | 2014 | 274 | 0.380 |
Why?
|
Attitude to Health | 1 | 2020 | 2025 | 0.380 |
Why?
|
Prevalence | 21 | 2024 | 15869 | 0.370 |
Why?
|
Maternal-Fetal Exchange | 3 | 2018 | 454 | 0.370 |
Why?
|
Feasibility Studies | 2 | 2021 | 5315 | 0.370 |
Why?
|
Treatment Failure | 8 | 2024 | 2661 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 5 | 2021 | 3231 | 0.360 |
Why?
|
Mothers | 6 | 2024 | 2209 | 0.360 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 879 | 0.360 |
Why?
|
Cisplatin | 1 | 2016 | 1660 | 0.350 |
Why?
|
Epidemics | 5 | 2022 | 517 | 0.350 |
Why?
|
Weaning | 1 | 2010 | 102 | 0.340 |
Why?
|
Phylogeny | 9 | 2024 | 2843 | 0.330 |
Why?
|
Milk, Human | 7 | 2012 | 490 | 0.330 |
Why?
|
Lidocaine | 1 | 2012 | 546 | 0.320 |
Why?
|
Male | 80 | 2024 | 364731 | 0.320 |
Why?
|
Genotype | 15 | 2024 | 13045 | 0.320 |
Why?
|
HIV | 9 | 2022 | 1597 | 0.320 |
Why?
|
Drug Therapy, Combination | 12 | 2022 | 6316 | 0.320 |
Why?
|
Proviruses | 5 | 2023 | 320 | 0.320 |
Why?
|
Brachytherapy | 1 | 2016 | 1220 | 0.320 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2819 | 0.310 |
Why?
|
Health Services Accessibility | 5 | 2024 | 5520 | 0.310 |
Why?
|
Pregnancy Complications | 4 | 2023 | 2973 | 0.310 |
Why?
|
Edema | 1 | 2012 | 765 | 0.310 |
Why?
|
Public Health | 2 | 2020 | 2679 | 0.300 |
Why?
|
Hepatitis Delta Virus | 2 | 2024 | 24 | 0.300 |
Why?
|
Prenatal Diagnosis | 1 | 2015 | 1275 | 0.290 |
Why?
|
Antigens, CD | 2 | 2018 | 4035 | 0.290 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2005 | 843 | 0.290 |
Why?
|
Hepatitis B Surface Antigens | 4 | 2023 | 294 | 0.290 |
Why?
|
Communicable Disease Control | 3 | 2020 | 857 | 0.280 |
Why?
|
Pregnant Women | 5 | 2024 | 576 | 0.280 |
Why?
|
Hepatitis B Antibodies | 3 | 2023 | 156 | 0.270 |
Why?
|
CD4-Positive T-Lymphocytes | 6 | 2023 | 4415 | 0.270 |
Why?
|
Mutation | 16 | 2024 | 30237 | 0.270 |
Why?
|
Disease Transmission, Infectious | 1 | 2012 | 560 | 0.260 |
Why?
|
Africa | 5 | 2018 | 725 | 0.260 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 983 | 0.260 |
Why?
|
Risk Management | 1 | 2009 | 558 | 0.260 |
Why?
|
Middle Aged | 39 | 2024 | 223487 | 0.250 |
Why?
|
HIV Integrase Inhibitors | 3 | 2024 | 165 | 0.240 |
Why?
|
Hypertension | 2 | 2023 | 8616 | 0.240 |
Why?
|
Hepatitis D | 1 | 2024 | 23 | 0.240 |
Why?
|
Pneumonia | 1 | 2016 | 2163 | 0.230 |
Why?
|
Maternal Mortality | 2 | 2024 | 310 | 0.230 |
Why?
|
Receptors, CXCR4 | 3 | 2016 | 729 | 0.230 |
Why?
|
Gestational Age | 3 | 2021 | 3621 | 0.230 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2043 | 0.230 |
Why?
|
Congenital Abnormalities | 2 | 2019 | 703 | 0.220 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.220 |
Why?
|
Africa South of the Sahara | 7 | 2018 | 752 | 0.210 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2003 | 50 | 0.210 |
Why?
|
Dietary Supplements | 3 | 2025 | 3445 | 0.210 |
Why?
|
E-Selectin | 2 | 2023 | 577 | 0.210 |
Why?
|
Receptors, HIV | 2 | 2016 | 159 | 0.210 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2023 | 693 | 0.210 |
Why?
|
Deoxycytidine | 5 | 2014 | 887 | 0.210 |
Why?
|
Dog Diseases | 1 | 2023 | 143 | 0.200 |
Why?
|
Malaria | 3 | 2022 | 1249 | 0.200 |
Why?
|
Alanine | 2 | 2024 | 614 | 0.200 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 135 | 0.200 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 381 | 0.200 |
Why?
|
HIV Antibodies | 7 | 2024 | 1341 | 0.190 |
Why?
|
Antiviral Agents | 6 | 2024 | 3072 | 0.190 |
Why?
|
Iron | 3 | 2025 | 1813 | 0.190 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2023 | 1134 | 0.190 |
Why?
|
Rural Population | 8 | 2024 | 2325 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 4 | 2016 | 6525 | 0.190 |
Why?
|
Birth Weight | 3 | 2023 | 2121 | 0.190 |
Why?
|
Leukocytes, Mononuclear | 4 | 2023 | 1854 | 0.180 |
Why?
|
Health Facility Merger | 2 | 1991 | 47 | 0.180 |
Why?
|
Prospective Studies | 16 | 2023 | 54924 | 0.180 |
Why?
|
Cross-Sectional Studies | 16 | 2024 | 26379 | 0.180 |
Why?
|
Albuminuria | 1 | 2024 | 658 | 0.170 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 62 | 0.170 |
Why?
|
Risk Factors | 22 | 2024 | 74944 | 0.170 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 214 | 0.170 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 133 | 0.170 |
Why?
|
Tetanus Toxoid | 1 | 2020 | 188 | 0.170 |
Why?
|
Survival Analysis | 3 | 2017 | 10099 | 0.160 |
Why?
|
Polymerase Chain Reaction | 6 | 2020 | 6082 | 0.160 |
Why?
|
Disease Reservoirs | 1 | 2019 | 123 | 0.160 |
Why?
|
Inflammasomes | 1 | 2024 | 540 | 0.160 |
Why?
|
Hepatitis B Vaccines | 1 | 2020 | 178 | 0.160 |
Why?
|
Awards and Prizes | 1 | 2023 | 365 | 0.160 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 334 | 0.160 |
Why?
|
Treatment Outcome | 20 | 2018 | 65379 | 0.160 |
Why?
|
Molecular Epidemiology | 1 | 2001 | 473 | 0.160 |
Why?
|
Condoms | 2 | 2022 | 337 | 0.150 |
Why?
|
Child, Preschool | 14 | 2022 | 42669 | 0.150 |
Why?
|
Hospitalization | 6 | 2021 | 10840 | 0.150 |
Why?
|
Quarantine | 1 | 2020 | 186 | 0.150 |
Why?
|
Mortality | 1 | 2010 | 2911 | 0.150 |
Why?
|
Immune Evasion | 1 | 2022 | 375 | 0.150 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.150 |
Why?
|
Pyrimidinones | 2 | 2011 | 386 | 0.150 |
Why?
|
Contact Tracing | 1 | 2020 | 275 | 0.150 |
Why?
|
Population Surveillance | 4 | 2019 | 2596 | 0.150 |
Why?
|
Parents | 1 | 2012 | 3595 | 0.150 |
Why?
|
Child Mortality | 2 | 2018 | 204 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 324 | 0.140 |
Why?
|
Government Programs | 1 | 2019 | 278 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2022 | 10397 | 0.140 |
Why?
|
Telemedicine | 1 | 2015 | 3109 | 0.140 |
Why?
|
Sexual Behavior | 2 | 2018 | 2197 | 0.140 |
Why?
|
Neural Tube Defects | 1 | 2019 | 255 | 0.140 |
Why?
|
AIDS Serodiagnosis | 3 | 2020 | 220 | 0.140 |
Why?
|
Child | 19 | 2024 | 80917 | 0.140 |
Why?
|
Prenatal Care | 1 | 2024 | 1162 | 0.140 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 414 | 0.140 |
Why?
|
Infant, Low Birth Weight | 2 | 2018 | 871 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 103 | 0.140 |
Why?
|
Syphilis | 1 | 2019 | 243 | 0.130 |
Why?
|
Extracellular Matrix | 1 | 2024 | 1738 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2024 | 1536 | 0.130 |
Why?
|
Drug Interactions | 1 | 2021 | 1419 | 0.130 |
Why?
|
Proportional Hazards Models | 6 | 2019 | 12543 | 0.130 |
Why?
|
Genes, env | 2 | 2013 | 96 | 0.130 |
Why?
|
Linear Models | 3 | 2017 | 5884 | 0.130 |
Why?
|
Antimalarials | 1 | 2022 | 909 | 0.130 |
Why?
|
Health Personnel | 2 | 2020 | 3384 | 0.130 |
Why?
|
Qualitative Research | 2 | 2024 | 3140 | 0.130 |
Why?
|
Serologic Tests | 1 | 2018 | 382 | 0.130 |
Why?
|
Choice Behavior | 1 | 2021 | 848 | 0.130 |
Why?
|
Naloxone | 1 | 2018 | 372 | 0.130 |
Why?
|
Neoplasms | 4 | 2019 | 22371 | 0.120 |
Why?
|
Hepacivirus | 1 | 2022 | 1344 | 0.120 |
Why?
|
Chemoprevention | 1 | 2017 | 327 | 0.120 |
Why?
|
Placenta | 2 | 2023 | 1725 | 0.120 |
Why?
|
Case-Control Studies | 7 | 2018 | 22290 | 0.120 |
Why?
|
Nervous System | 1 | 2018 | 544 | 0.120 |
Why?
|
Travel | 2 | 2019 | 805 | 0.120 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3415 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2017 | 337 | 0.110 |
Why?
|
Phlebotomy | 1 | 2015 | 138 | 0.110 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 830 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2022 | 1384 | 0.110 |
Why?
|
Diarrhea | 1 | 2020 | 1320 | 0.110 |
Why?
|
Mycobacterium tuberculosis | 2 | 2003 | 1930 | 0.110 |
Why?
|
Counseling | 2 | 2015 | 1554 | 0.110 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 560 | 0.110 |
Why?
|
South Africa | 4 | 2022 | 1873 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 135 | 0.110 |
Why?
|
Antibodies, Neutralizing | 4 | 2024 | 2009 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1377 | 0.110 |
Why?
|
Causality | 1 | 2019 | 1254 | 0.110 |
Why?
|
Feces | 2 | 2017 | 1511 | 0.110 |
Why?
|
Endpoint Determination | 2 | 2014 | 592 | 0.100 |
Why?
|
Intention | 1 | 2016 | 347 | 0.100 |
Why?
|
Peripartum Period | 1 | 2014 | 137 | 0.100 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1772 | 0.100 |
Why?
|
Risk-Taking | 1 | 2018 | 1023 | 0.100 |
Why?
|
Medication Adherence | 3 | 2017 | 2187 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2013 | 2592 | 0.100 |
Why?
|
Immunity, Innate | 3 | 2022 | 3080 | 0.100 |
Why?
|
Mastitis | 1 | 2012 | 42 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1194 | 0.100 |
Why?
|
Rural Health | 2 | 2012 | 302 | 0.100 |
Why?
|
Time Factors | 9 | 2019 | 40220 | 0.100 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2014 | 425 | 0.100 |
Why?
|
Placental Insufficiency | 1 | 2012 | 50 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1613 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2008 | 0.100 |
Why?
|
Delivery, Obstetric | 1 | 2019 | 954 | 0.100 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7477 | 0.100 |
Why?
|
Immunity, Humoral | 1 | 2016 | 610 | 0.100 |
Why?
|
Hospital Administration | 2 | 1986 | 351 | 0.090 |
Why?
|
Monocytes | 2 | 2019 | 2605 | 0.090 |
Why?
|
Pilot Projects | 3 | 2021 | 8741 | 0.090 |
Why?
|
Bone Density | 1 | 2024 | 3573 | 0.090 |
Why?
|
Sensitivity and Specificity | 6 | 2022 | 14729 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2018 | 1375 | 0.090 |
Why?
|
Double-Blind Method | 3 | 2017 | 12466 | 0.090 |
Why?
|
HIV Seronegativity | 1 | 2011 | 210 | 0.090 |
Why?
|
Research | 1 | 2019 | 1979 | 0.090 |
Why?
|
Decision Making, Organizational | 1 | 1991 | 136 | 0.090 |
Why?
|
Immunoglobulin M | 3 | 2023 | 1528 | 0.090 |
Why?
|
Administration, Topical | 1 | 2012 | 704 | 0.090 |
Why?
|
Micronutrients | 2 | 2025 | 390 | 0.090 |
Why?
|
Buprenorphine | 1 | 2018 | 667 | 0.090 |
Why?
|
Virology | 1 | 2010 | 76 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1063 | 0.090 |
Why?
|
Interferon-gamma | 2 | 2020 | 3161 | 0.090 |
Why?
|
Virus Internalization | 2 | 2012 | 503 | 0.090 |
Why?
|
Host-Pathogen Interactions | 2 | 2016 | 1469 | 0.090 |
Why?
|
Developmental Disabilities | 2 | 2016 | 1518 | 0.080 |
Why?
|
Genetic Variation | 4 | 2019 | 6610 | 0.080 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7852 | 0.080 |
Why?
|
Blood Pressure | 2 | 2023 | 8543 | 0.080 |
Why?
|
Viral Tropism | 2 | 2023 | 102 | 0.080 |
Why?
|
Cluster Analysis | 2 | 2018 | 2732 | 0.080 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1892 | 0.080 |
Why?
|
Organizational Objectives | 1 | 1991 | 426 | 0.080 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15662 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39354 | 0.080 |
Why?
|
RNA | 3 | 2023 | 2722 | 0.080 |
Why?
|
World Health Organization | 3 | 2022 | 1328 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 219 | 0.080 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 939 | 0.080 |
Why?
|
Perinatal Care | 1 | 2011 | 245 | 0.080 |
Why?
|
Personal Satisfaction | 1 | 2013 | 643 | 0.080 |
Why?
|
Interleukin-10 | 1 | 2014 | 1184 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1238 | 0.080 |
Why?
|
Gene Frequency | 2 | 2019 | 3623 | 0.080 |
Why?
|
Health Services Research | 2 | 2019 | 1815 | 0.070 |
Why?
|
Escherichia coli | 2 | 2017 | 4213 | 0.070 |
Why?
|
Drug Combinations | 2 | 2020 | 2089 | 0.070 |
Why?
|
Interleukin-6 | 2 | 2018 | 3229 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6847 | 0.070 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2011 | 392 | 0.070 |
Why?
|
Death | 1 | 2012 | 683 | 0.070 |
Why?
|
Thailand | 2 | 2018 | 288 | 0.070 |
Why?
|
Exanthema | 1 | 2012 | 503 | 0.070 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 2862 | 0.070 |
Why?
|
Cohort Studies | 12 | 2021 | 41753 | 0.070 |
Why?
|
Voluntary Programs | 1 | 2006 | 48 | 0.070 |
Why?
|
Capsid Proteins | 2 | 2011 | 468 | 0.070 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2013 | 862 | 0.070 |
Why?
|
Hospital-Physician Joint Ventures | 1 | 1986 | 30 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4428 | 0.060 |
Why?
|
Genome, Viral | 2 | 2020 | 674 | 0.060 |
Why?
|
Motivation | 1 | 2016 | 2020 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9262 | 0.060 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 1743 | 0.060 |
Why?
|
Bacteria | 1 | 2016 | 2216 | 0.060 |
Why?
|
Medical Staff, Hospital | 2 | 1991 | 603 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1388 | 0.060 |
Why?
|
Sex Factors | 3 | 2019 | 10632 | 0.060 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 1546 | 0.060 |
Why?
|
Hospital Restructuring | 1 | 1984 | 11 | 0.060 |
Why?
|
Professional Corporations | 1 | 1984 | 9 | 0.060 |
Why?
|
Creatinine | 2 | 2024 | 1918 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 2 | 2020 | 789 | 0.060 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 7140 | 0.060 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 587 | 0.060 |
Why?
|
Lobbying | 1 | 1984 | 32 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8747 | 0.060 |
Why?
|
Postnatal Care | 1 | 2006 | 273 | 0.060 |
Why?
|
Neonatal Screening | 2 | 2020 | 619 | 0.060 |
Why?
|
Vaccines, DNA | 1 | 2005 | 279 | 0.060 |
Why?
|
Family Characteristics | 2 | 2021 | 1003 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12077 | 0.060 |
Why?
|
DNA Primers | 1 | 2008 | 2828 | 0.050 |
Why?
|
Labor, Obstetric | 1 | 2007 | 323 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1255 | 0.050 |
Why?
|
Adenoviruses, Human | 1 | 2005 | 257 | 0.050 |
Why?
|
Comorbidity | 2 | 2016 | 10590 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2018 | 4310 | 0.050 |
Why?
|
Tropism | 1 | 2023 | 44 | 0.050 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2188 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2014 | 2100 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4861 | 0.050 |
Why?
|
Parturition | 2 | 2019 | 455 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2018 | 4543 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13677 | 0.050 |
Why?
|
Michigan | 4 | 1986 | 330 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2013 | 4786 | 0.050 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2024 | 199 | 0.050 |
Why?
|
Interleukin-18 | 1 | 2024 | 251 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Infant Food | 1 | 2003 | 139 | 0.050 |
Why?
|
Antibiotics, Antitubercular | 1 | 2003 | 100 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4355 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 620 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2014 | 3573 | 0.050 |
Why?
|
Aged | 8 | 2024 | 171502 | 0.050 |
Why?
|
Professional Practice | 1 | 1984 | 314 | 0.050 |
Why?
|
Patient Compliance | 3 | 2013 | 2697 | 0.050 |
Why?
|
Retrospective Studies | 9 | 2023 | 81760 | 0.050 |
Why?
|
Primary Health Care | 1 | 2019 | 4746 | 0.050 |
Why?
|
Logistic Models | 6 | 2016 | 13290 | 0.050 |
Why?
|
Antibodies, Viral | 2 | 2021 | 3214 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2211 | 0.050 |
Why?
|
Infant Care | 1 | 2003 | 182 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 276 | 0.050 |
Why?
|
DNA Fingerprinting | 1 | 2001 | 114 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3433 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3311 | 0.050 |
Why?
|
Virus Replication | 2 | 2021 | 2458 | 0.040 |
Why?
|
Sputum | 1 | 2003 | 517 | 0.040 |
Why?
|
Switzerland | 1 | 2021 | 323 | 0.040 |
Why?
|
Bangladesh | 1 | 2022 | 742 | 0.040 |
Why?
|
Policy Making | 1 | 1984 | 546 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 204 | 0.040 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2016 | 925 | 0.040 |
Why?
|
Dengue | 1 | 2003 | 258 | 0.040 |
Why?
|
Viral Vaccines | 1 | 2005 | 596 | 0.040 |
Why?
|
Educational Status | 2 | 2023 | 2515 | 0.040 |
Why?
|
Neutralization Tests | 2 | 2016 | 739 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2013 | 5349 | 0.040 |
Why?
|
Papillomavirus Infections | 1 | 2011 | 1640 | 0.040 |
Why?
|
Abortion, Spontaneous | 1 | 2024 | 535 | 0.040 |
Why?
|
Zambia | 1 | 2020 | 273 | 0.040 |
Why?
|
Cost-Benefit Analysis | 3 | 2022 | 5536 | 0.040 |
Why?
|
Hospitals, District | 1 | 2019 | 114 | 0.040 |
Why?
|
Anthropometry | 2 | 2016 | 1346 | 0.040 |
Why?
|
Nucleosides | 1 | 2019 | 130 | 0.040 |
Why?
|
Multilevel Analysis | 1 | 2019 | 148 | 0.040 |
Why?
|
Health Promotion | 1 | 2010 | 2210 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7609 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2020 | 14783 | 0.040 |
Why?
|
Nitriles | 1 | 2023 | 980 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2022 | 995 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2024 | 1758 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3845 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 468 | 0.040 |
Why?
|
HIV Antigens | 1 | 2018 | 328 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 438 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 360 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2008 | 4249 | 0.040 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2001 | 664 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21207 | 0.040 |
Why?
|
Cytokines | 1 | 2012 | 7452 | 0.030 |
Why?
|
Kenya | 1 | 2020 | 757 | 0.030 |
Why?
|
Politics | 1 | 1984 | 822 | 0.030 |
Why?
|
DNA Transposable Elements | 1 | 2001 | 764 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1525 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2024 | 2741 | 0.030 |
Why?
|
Epitopes | 1 | 2023 | 2527 | 0.030 |
Why?
|
BCG Vaccine | 1 | 2020 | 381 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2005 | 1397 | 0.030 |
Why?
|
Fetal Death | 1 | 2018 | 434 | 0.030 |
Why?
|
Asia | 1 | 2018 | 630 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1755 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1599 | 0.030 |
Why?
|
Vincristine | 1 | 2018 | 1040 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2179 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2005 | 3403 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 969 | 0.030 |
Why?
|
Fever | 1 | 2003 | 1614 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 151 | 0.030 |
Why?
|
Uganda | 1 | 2020 | 1361 | 0.030 |
Why?
|
Schools | 1 | 2023 | 1498 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2019 | 500 | 0.030 |
Why?
|
Australia | 1 | 2018 | 1265 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2022 | 1344 | 0.030 |
Why?
|
Weight Gain | 1 | 2024 | 2359 | 0.030 |
Why?
|
United States | 7 | 2018 | 73039 | 0.030 |
Why?
|
Prednisone | 1 | 2018 | 1567 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 653 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15453 | 0.030 |
Why?
|
Prognosis | 1 | 2014 | 30009 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2020 | 1895 | 0.030 |
Why?
|
Research Design | 2 | 2020 | 6209 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15949 | 0.030 |
Why?
|
Health Status Disparities | 1 | 2025 | 1885 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9613 | 0.030 |
Why?
|
Sexual Partners | 1 | 2018 | 805 | 0.030 |
Why?
|
Plaque, Atherosclerotic | 1 | 2024 | 1551 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11244 | 0.030 |
Why?
|
Social Stigma | 1 | 2019 | 788 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8052 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2018 | 2227 | 0.030 |
Why?
|
Program Development | 1 | 2019 | 1300 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 640 | 0.030 |
Why?
|
Self Report | 1 | 2024 | 3773 | 0.020 |
Why?
|
China | 1 | 2018 | 2395 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
American Heart Association | 1 | 2017 | 1050 | 0.020 |
Why?
|
Birth Certificates | 1 | 2011 | 71 | 0.020 |
Why?
|
Trustees | 1 | 1991 | 6 | 0.020 |
Why?
|
Specimen Handling | 1 | 2016 | 707 | 0.020 |
Why?
|
Fetus | 1 | 2019 | 1883 | 0.020 |
Why?
|
Insurance, Hospitalization | 1 | 1991 | 30 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5402 | 0.020 |
Why?
|
Risk Assessment | 3 | 2018 | 24318 | 0.020 |
Why?
|
Doxorubicin | 1 | 2018 | 2234 | 0.020 |
Why?
|
Caregivers | 1 | 2024 | 2302 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2004 | 2171 | 0.020 |
Why?
|
Pyrimidines | 1 | 2023 | 3048 | 0.020 |
Why?
|
Philosophy | 1 | 1991 | 69 | 0.020 |
Why?
|
Hospital Administrators | 1 | 1991 | 57 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1078 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 659 | 0.020 |
Why?
|
Goals | 1 | 2016 | 717 | 0.020 |
Why?
|
Herpes Genitalis | 1 | 2011 | 149 | 0.020 |
Why?
|
Government | 1 | 1991 | 161 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1381 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 491 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17623 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2011 | 191 | 0.020 |
Why?
|
Investments | 1 | 1991 | 149 | 0.020 |
Why?
|
Community-Institutional Relations | 1 | 1991 | 209 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 352 | 0.020 |
Why?
|
Body Height | 1 | 2016 | 1565 | 0.020 |
Why?
|
Personnel, Hospital | 1 | 1991 | 285 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3437 | 0.020 |
Why?
|
Drug Utilization | 1 | 2015 | 1189 | 0.020 |
Why?
|
Health Care Costs | 1 | 2022 | 3239 | 0.020 |
Why?
|
Bottle Feeding | 1 | 2008 | 67 | 0.020 |
Why?
|
Ownership | 1 | 1991 | 338 | 0.020 |
Why?
|
Base Sequence | 1 | 2019 | 12422 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1524 | 0.020 |
Why?
|
Luciferases | 1 | 2010 | 713 | 0.020 |
Why?
|
Alleles | 2 | 2011 | 6894 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2748 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2923 | 0.020 |
Why?
|
Body Size | 1 | 2011 | 463 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11878 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2566 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8890 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 751 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 24 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1397 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2014 | 1820 | 0.020 |
Why?
|
Smoking | 1 | 2004 | 9092 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2007 | 177 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2008 | 414 | 0.020 |
Why?
|
Tuberculosis | 1 | 2019 | 2029 | 0.020 |
Why?
|
Maternal-Child Health Centers | 1 | 2006 | 42 | 0.020 |
Why?
|
HIV Seroprevalence | 1 | 2006 | 89 | 0.020 |
Why?
|
Triglycerides | 1 | 2014 | 2464 | 0.020 |
Why?
|
Health Policy | 1 | 2019 | 2697 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2010 | 1524 | 0.020 |
Why?
|
Algorithms | 2 | 2020 | 14164 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 787 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2008 | 606 | 0.020 |
Why?
|
Ethambutol | 1 | 2005 | 59 | 0.020 |
Why?
|
Pyrazinamide | 1 | 2005 | 60 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2007 | 1065 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1641 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2118 | 0.020 |
Why?
|
Plasmids | 1 | 2010 | 2269 | 0.020 |
Why?
|
Marital Status | 1 | 2006 | 426 | 0.020 |
Why?
|
Body Weight | 1 | 2016 | 4627 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2005 | 361 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 2403 | 0.010 |
Why?
|
Terminology as Topic | 1 | 1991 | 1542 | 0.010 |
Why?
|
Immunodominant Epitopes | 1 | 2005 | 244 | 0.010 |
Why?
|
Occupations | 1 | 2006 | 516 | 0.010 |
Why?
|
Legislation as Topic | 1 | 1984 | 76 | 0.010 |
Why?
|
Life Expectancy | 1 | 2011 | 1248 | 0.010 |
Why?
|
Helicobacter pylori | 1 | 2007 | 380 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9343 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 2005 | 404 | 0.010 |
Why?
|
Fraud | 1 | 1984 | 66 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2007 | 992 | 0.010 |
Why?
|
Isoniazid | 1 | 2005 | 288 | 0.010 |
Why?
|
Maternal Age | 1 | 2006 | 805 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6340 | 0.010 |
Why?
|
Sri Lanka | 1 | 2003 | 93 | 0.010 |
Why?
|
Rifampin | 1 | 2005 | 352 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5367 | 0.010 |
Why?
|
Cause of Death | 1 | 2013 | 3721 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1596 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10266 | 0.010 |
Why?
|
Hemoglobins | 1 | 2008 | 1531 | 0.010 |
Why?
|
Taxes | 1 | 1984 | 220 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 764 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16726 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7454 | 0.010 |
Why?
|
Poverty | 1 | 2013 | 2720 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1478 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2012 | 13422 | 0.010 |
Why?
|
Urban Health | 1 | 2003 | 535 | 0.010 |
Why?
|
Developing Countries | 1 | 2013 | 2910 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 1980 | 7951 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5151 | 0.010 |
Why?
|
Binding Sites | 1 | 2008 | 6019 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2006 | 2434 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2006 | 1406 | 0.010 |
Why?
|
Animals | 3 | 2023 | 169285 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18415 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4585 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6229 | 0.010 |
Why?
|
Vagina | 1 | 2003 | 850 | 0.010 |
Why?
|
Body Mass Index | 1 | 2014 | 13053 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2005 | 6231 | 0.010 |
Why?
|
Cell Line | 1 | 2010 | 15602 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4568 | 0.010 |
Why?
|
Child Health Services | 1 | 1980 | 645 | 0.010 |
Why?
|
Informed Consent | 1 | 1980 | 1010 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 4206 | 0.010 |
Why?
|
Odds Ratio | 1 | 2004 | 9669 | 0.010 |
Why?
|
Hospitals | 1 | 1984 | 3886 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2005 | 22380 | 0.000 |
Why?
|
Mice | 1 | 2005 | 82049 | 0.000 |
Why?
|